Celldex Therapeutics, Inc.
NASDAQ:CLDXBiotechnology
Healthcare
$27.96 +0.47%
+$0.16 today
- Market cap
- $2.20B
- Beta
- 0.93
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$4.26
52W Low $19.52High $35.79
Volume 0.75M
Average 0.94M
Income Statement
Follow revenue through to earnings.
Revenue
$1.50M
FY 2025 · Annual
-78.6% YoYOperating Income
-$287.40M
FY 2025 · Annual
Net Income
-$258.80M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.65M | 2.36M | 6.88M | 7.02M | 1.5M |
| Cost of Revenue | 53.31M | 82.26M | 118.01M | 163.55M | 0 |
| Gross Profit | (48.66M) | (79.9M) | (111.13M) | (156.53M) | 1.5M |
| Gross Margin | -1046.2% | -3389.9% | -1614.5% | -2229.8% | 100.0% |
| Research & Development | 56.81M | 82.26M | 118.01M | 163.55M | 245.1M |
| Selling, General & Admin | 20.49M | 27.2M | 30.91M | 38.55M | 43.8M |
| Operating Expenses | 22.58M | 35.33M | 43.41M | 38.55M | 288.9M |
| Depreciation & Amortization | 3.07M | 2.9M | 3.01M | 3.18M | 3.38M |
| EBITDA | (66.08M) | (104.2M) | (139.03M) | (154.69M) | (255.42M) |
| EBITDA Margin | -1420.8% | -4420.9% | -2020.0% | -2203.5% | -17028.0% |
| Operating Income | (71.24M) | (115.23M) | (154.54M) | (195.08M) | (287.4M) |
| Operating Margin | -1531.8% | -4889.0% | -2245.3% | -2778.9% | -19160.0% |
| Interest Income | 505K | 2.91M | 13.11M | 37.22M | 28.61M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 505K | 2.91M | 13.11M | 37.22M | 28.6M |
| Income Before Tax | (70.74M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Pre-Tax Margin | -1520.9% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| Income Tax Expense | (227K) | 0 | 0 | 0 | 0 |
| Net Income | (70.51M) | (112.33M) | (141.43M) | (157.86M) | (258.8M) |
| Net Margin | -1516.0% | -4765.6% | -2054.8% | -2248.8% | -17253.3% |
| EPS (Basic) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| EPS (Diluted) | (1.64) | (2.40) | (2.92) | (2.45) | (3.90) |
| 42.87M | 46.89M | 48.45M | 64.4M | 66.5M | |
| 42.87M | 46.89M | 48.45M | 64.4M | 66.5M |
CLDX Earnings Waterfall · TTM
NASDAQ:CLDX · Revenue to Net Income
Key Ratios
EPS$-4.31
Gross Margin-1348.3%
Net Margin-241787.8%
P/E Ratio-7.6
P/S Ratio74125.6
Analysis
$112.0K of revenue converted into -$309.1M of net income for the selected period. Gross margin is -1348.3% and net margin is -241787.8%, showing how much revenue survives after costs and taxes. EPS is $-4.31, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 8-K | Current report | Sep 22, 2026 |
How much revenue does CLDX generate?
Celldex Therapeutics, Inc. (CLDX) reported $1.50M of revenue in fiscal 2025.
Is CLDX profitable?
Celldex Therapeutics, Inc. (CLDX) reported -$258.80M of net income, with a net margin of -17253.3%.
Continue the stock analysis
Jump to another research area for this company.